Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.
1. A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, wherein the pre-filled pharmaceutical package comprises:
a wall comprising a thermoplastic material, having an interior surface enclosing at least a portion of a lumen;
a tie coating or layer on the wall interior surface comprising SiO x C y H z , in which x is from about 0.5 to about 2.4 as measured by X-ray photoelectron spectroscopy (XPS), y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of Rutherford backscattering spectrometry (RBS) or hydrogen forward scattering (HFS);
a barrier coating or layer of SiO x , in which x is from about 1.5 to about 2.9 as measured by XPS, the barrier coating or layer positioned between the tie coating or layer and the lumen;
a pH protective coating or layer of SiO x C y H z , in which x is from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of RBS or HFS, positioned between the barrier coating or layer and the lumen;
a liquid formulation of a VEGF-antagonist in the lumen; and
a closure closing the lumen;
wherein the liquid formulation of a VEGF-antagonist in the lumen has less aggregates after storage for 3 months at 25 or 40° C. than the same liquid formulation stored for the same amount of time and under the same conditions in a lumen of a pre-filled pharmaceutical package having a wall made of borosilicate glass and which lacks the tie coating or layer, the barrier coating or layer, and the pH protective coating or layer.
2. The prefilled pharmaceutical package according to claim 1 , wherein the VEGF antagonist is Ranibizumab, Aflibercept or Bevacizumab.
3. The prefilled pharmaceutical package according to claim 1 , wherein the thermoplastic material is a polyolefin, polypropylene or a polyester or any combination or copolymer thereof.
4. The prefilled pharmaceutical package according to claim 3 , wherein the polyolefin is a cyclic olefin polymer or a cyclic olefin copolymer.
5. The prefilled pharmaceutical package according to claim 1 , wherein the closure is a stopper, and in which the front face of the stopper is covered with a fluoropolymer coating or layer, wherein the front face is facing the liquid formulation.
6. The pre-filled pharmaceutical package according to claim 1 , having a nominal maximum fill volume of 0.5 or 1 mL.
7. The pre-filled pharmaceutical package according to claim 1 , being a vial or a cartridge.
8. The pre-filled pharmaceutical package according to claim 1 , in which the VEGF-antagonist is Ranibizumab and the liquid formulation of Ranibizumab contains no more than 50 particles ≥10 μm diameter per mL, no more than 5 particles ≥25 μm diameter per mL, and/or no more than 2 particles ≥50 μm diameter per mL, during shelf life, measured by microscopic inspection.
9. The pre-filled pharmaceutical package according to claim 1 , which is free of silicone oil on all product contacting surfaces of the pre-filled pharmaceutical package.
10. The pre-filled pharmaceutical package according to claim 1 , which is free of baked-on silicone.
11. The pre-filled pharmaceutical package according to claim 1 , which is terminally sterilized.
12. Kit comprising one or more pre-filled pharmaceutical packages according to claim 1 .
13. The prefilled pharmaceutical package according to claim 1 , further comprising a lubricity coating or layer positioned between the pH protective coating or layer and the lumen.
14. The pre-filled pharmaceutical package according to claim 13 , wherein the lubricity coating or layer has the atomic proportions SiO x C y H z , in which x is from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of RBS or HFS.
15. The prefilled pharmaceutical package according to claim 13 , wherein the lubricity coating or layer is prepared by plasma enhanced chemical vapor deposition (PECVD) from an organosilicon precursor.
16. The prefilled pharmaceutical package according to claim 15 , wherein the lubricity coating or layer is prepared by PECVD from octamethylcyclotetrasiloxane (OMCTS) as the organosilicon precursor.
17. The prefilled pharmaceutical package according to claim 1 , comprising a liquid formulation of Ranibizumab in the lumen.
18. The prefilled pharmaceutical package according to claim 17 , in which the liquid formulation of Ranibizumab in the lumen comprises Ranibizumab at a concentration of 6 or 10 mg/ml.
19. The pre-filled pharmaceutical package according to claim 1 , comprising a liquid formulation of Aflibercept in the lumen.
20. The pre-filled pharmaceutical package according to claim 19 , in which the liquid formulation of Aflibercept in the lumen comprises Aflibercept at a concentration of 40 mg/ml.
21. The pre-filled pharmaceutical package according to claim 19 , in which the liquid formulation of Aflibercept in the lumen comprises
40 mg/ml Aflibercept;
10 mM sodium phosphate buffer,
40 mM NaCl;
0.03% polysorbate 20;
5% sucrose; and
water for injection.
22. The pre-filled pharmaceutical package according to claim 21 , wherein the pH of the liquid formulation of Aflibercept has been adjusted to 6.2.
23. The pre-filled pharmaceutical package according to claim 19 , in which the liquid formulation of Aflibercept in the lumen comprises
40 mg/ml Aflibercept;
10 mM histidine buffer,
40 mM NaCl;
0.03% polysorbate 20;
5% sucrose; and
water for injection.
24. The pre-filled pharmaceutical package according to claim 23 , wherein the pH of the liquid formulation of Aflibercept has been adjusted to 6.2.
25. The pre-filled pharmaceutical package according to claim 1 , comprising a liquid formulation of Bevacizumab in the lumen.
26. The pre-filled pharmaceutical package according to claim 25 , in which the liquid formulation of Bevacizumab in the lumen comprises Bevacizumab at a concentration of 25 mg/ml.
27. The pre-filled pharmaceutical package according to claim 25 , in which the liquid formulation of Bevacizumab in the lumen comprises
25 mg/ml Bevacizumab;
240 mg α,α-trehalose dihydrate,
23.2 mg sodium phosphate (monobasic, monohydrate),
4.8 mg sodium phosphate (dibasic, anhydrous),
1.6 mg polysorbate 20, and
Water for Injection, USP.
28. The pre-filled pharmaceutical package according to claim 1 , further comprising an additional pharmacologically active agent.
29. The pre-filled pharmaceutical package according to claim 28 , wherein the additional pharmacologically active agent is a PDGF antagonist.
30. The pre-filled pharmaceutical package according to claim 1 , being a syringe.
31. The pre-filled pharmaceutical package according to claim 30 , comprising a plunger.
32. The pre-filled pharmaceutical package according to claim 31 , wherein the plunger comprises a side surface slidable along the wall.
33. The pre-filled pharmaceutical package according to claim 32 , wherein at least a portion of the side surface comprises a fluoropolymer lubricity coating or layer abutting the wall.
34. The pre-filled pharmaceutical package according to claim 30 , having a breakout force less than or equal to 15N for initiating travel of the stopper in the lumen.
35. The pre-filled pharmaceutical package according to claim 30 , having a plunger sliding force less than or equal to 15N for advancing the stopper in the lumen.
36. The pre-filled pharmaceutical package according to claim 30 , further comprising a staked needle or a luer connector.
37. The pre-filled pharmaceutical package of claim 1 for use in administering a liquid formulation of a VEGF-antagonist to a patient having an ocular disease.
38. The pre-filled pharmaceutical package for the use according to claim 37 , wherein the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME), visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), or visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia.
39. The pre-filled pharmaceutical package for the use according to claim 37 , wherein the VEGF antagonist is Ranibizumab which is administered in a volume of 0.05 mL.
40. The pre-filled pharmaceutical package for the use according to claim 37 , wherein the VEGF antagonist is Aflibercept which is administered in a volume of 0.05 mL.
41. The pre-filled pharmaceutical package for the use according to claim 37 , wherein the VEGF antagonist is Bevacizumab which is administered in a volume of 0.05 mL.
42. A liquid formulation of a VEGF-antagonist in a pre-filled pharmaceutical package according to claim 17 , in which the liquid formulation of Ranibizumab in the lumen further comprises:
a buffer in an amount effective to provide a pH of the liquid formulation in the range from about 5 to about 7;
a non-ionic surfactant in the range of 0.005 to 0.02 mg./mL of complete formulation, and
water for injection.
43. A liquid formulation of a VEGF-antagonist in a pre-filled pharmaceutical package according to claim 17 , in which the liquid formulation of Ranibizumab in the lumen comprises, per mL of formulation:
6 or 10 mg. Ranibizumab;
100 mg. α,α-trehalose dihydrate;
1.98 mg. L-histidine;
0.1 mg Polysorbate 20; and
water for injection qs to 1 mL.
44. A liquid formulation of a VEGF-antagonist in a pre-filled pharmaceutical package according to claim 17 , in which the liquid formulation of Ranibizumab has been adjusted to pH 5.5 with HCl.
45. A liquid formulation of a VEGF-antagonist in a pre-filled pharmaceutical package according to claim 17 , in which the liquid formulation of Ranibizumab in the lumen comprises, per mL of formulation:
6 or 10 mg. Ranibizumab;
100 mg. α,α-trehalose dihydrate;
0.32 mg. L-histidine
1.66 mg. L-histidine hydrochloride monohydrate;
0.1 mg Polysorbate 20; and
water for injection qs to 1 mL.